With this acquisition, Wilmington, Delaware-headquartered Noramco said, the company and its subsidiary Purisys will be able to offer additional service options such as drug product formulation development, clinical and commercial drug product manufacturing, and packaging from facilities in Mirabel, Québec, Canada and Whippany, New Jersey, US. Noramco said that it is re-establishing the Halo Pharmaceutical brand as part of this acquisition.

According to Noramco, its APIs are used by many of the leading brand and generic pharma companies as well as small to mid- scale pharma companies. Noramco’s APIs are used in over 350 products and sold in over 30 counties.

“This acquisition allows Noramco to provide our customers with more sourcing options beyond APIs. With these additional capabilities, Noramco/Purisys customers can develop drug product formulations for their APIs for both clinical and commercial purposes,” said Noramco CEO Lee Karras. “Having previously operated the Halo Pharmaceuticals business, I have a direct appreciation of the capabilities of both sites and look forward to working with existing and future customers while welcoming the almost 400 new employees to the Noramco group of companies.”